- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05623748
Establishment and Application of 3-Dimensional (3-D) Cell Culture Model of Clinical Circulating Tumor Cells (CTCs)
The goal of this observational study is to validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion in cancer patient with transitional cell carcinoma and patient without cancer.
This project first aims to study the clinical feasibility of utilizing a 3-D cell culture model for the isolation/purification of all possible CTCs in a blood sample in a label-free, viable, and high-purity manner. Through 3-D CTC culture, moreover, the cell number of CTCs can be adequately expanded. All these advantageous features are beyond what is currently possible by using the existing methods. In addition, the harvest of CTCs with above features is found valuable for the subsequent academic researches or clinical studies (e.g. molecular mechanisms underlying cancer metastasis, cancer-related gene mutation, biomarker discovery, and particularly CTCs-based chemotherapy drug testing). These could both facilitate and accelerate scientists to develop new therapeutic solutions for future cancer care.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Circulating tumor cells (CTCs), the rare cell species present in the blood, are considered to mainly contribute to cancer metastasis or relapse. Thus, the detection of CTCs is regarded as an essential clinical tool to detect metastatic cancer. Moreover, CTCs can be the therapeutic target of metastatic cancer care. Therefore, the use of viable CTCs as a biopsy to select therapeutic regimens (e.g. CTCs-based anti-cancer drug testing) opens up a promising route to realize personalized cancer therapy. With the recent advances in cell isolation or detection techniques, various novel approaches have been actively proposed to isolate/detect CTCs. Nevertheless, most of current methods might not be able to obtain the all possible, viable, and label-free CTCs with adequate cell purity and cell number for the subsequent CTCs-based anti-cancer drug testing or other bioassays. To tackle the above technical hurdles, the research project proposes the use of a specific 3-D cell culture technique for the isolation/purification, and cell number expansion of CTCs.
The working principle is based on our preliminary findings showing that the human leukocytes will die away in 3-D cell culture condition, whereas the CTCs will tend to aggregate and proliferate in such environment. Based on this phenomenon, the 3-D CTC cell culture can be used to isolate and purify the viable CTCs from the leukocyte background in a negative selection, and label-free manner, enabling the harvest of the all possible CTCs in a blood sample. Furthermore, the proliferation of CTCs in such 3-D cell culture can adequately expand the cell number of CTCs for the subsequent applications, which is currently impossible using the existing methods.
In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion. In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation. In the optimization process, investigators will explore the effect of cell culture model (e.g. static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g. glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC solation/purification and proliferation. As a whole, investigators hope the proposed research project can find out an efficient and effective approach to isolate/purify/expand clinical CTCs in a viable, label-free, and high-purity manner. These harvested CTCs are valuable for the subsequent analytical tasks.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Chia-Hsun Hsieh
- Phone Number: 0975366137
- Email: wisdom5000@gmail.com
Study Contact Backup
- Name: Hsuan-Chih Kuo
- Phone Number: 0975360665
- Email: hsuanchihkuo@gmail.com
Study Locations
-
-
-
New Taipei City, Taiwan, 236
- Recruiting
- Chang Gung Memorial Hospital
-
Contact:
- Hsuan-Chih Kuo
- Phone Number: 0975366137
- Email: wisdom2000@gmail.com
-
Contact:
- Chia-Hsun Hsieh
- Phone Number: 0975360665
- Email: hsuanchihkuo@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients who agreed with the content of informed consent of the study protocol
- patients who agreed the researcher to review the medical record
- adults >20 years old
- Patients have the right to asked withdrawing from the trial at any timepoints
- meet the following requirements (1)cancer participants:cancer patients with transitional cell carcinoma (2)healthy participants:participants without cancer
Exclusion Criteria:
- Patients who refused the collection of blood and the reviewing of medical record
- The investigators suggest to withdraw
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cancer for CTC culture
participants are cancer patients with transitional cell carcinoma
|
In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion.
In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation.
In the optimization process, investigators will explore the effect of cell culture model (e.g.
static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g.
glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
|
Healthy for CTC culture
enroll participants without cancer
|
In the 1st year research project, investigators will further validate and evaluate the clinical feasibility of using a 3-D cell culture model for CTCs isolation/purification and their cell number expansion.
In the 2nd and 3rd year research project, investigators will optimize the 3-D cell culture model so as to increase the performances of CTC isolation/purification and proliferation.
In the optimization process, investigators will explore the effect of cell culture model (e.g.
static or perfusion cell culture, and 3-D cell culture using different 3-D scaffolding materials) or biochemical factors (e.g.
glucose concentration, serum concentration, pH, or the supplements of growth factors/cytokines) on the the performances of CTC isolation/purification and proliferation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the effect of cell culture model for the Cell viability
Time Frame: 3 month
|
optimize the 3-D cell culture model to measure the Cell viability
|
3 month
|
the effect of cell culture model for the Cell viability
Time Frame: 6 month
|
optimize the 3-D cell culture model to measure the Cell viability
|
6 month
|
the effect of cell culture model for the Cell number
Time Frame: 3 month
|
optimize the 3-D cell culture model to measure the Cell number
|
3 month
|
the effect of cell culture model for the Cell number
Time Frame: 6 month
|
optimize the 3-D cell culture model to measure the Cell number
|
6 month
|
the effect of cell culture model for the Cell viability
Time Frame: baseline
|
optimize the 3-D cell culture model to measure the Cell viability
|
baseline
|
the effect of cell culture model for the Cell number
Time Frame: baseline
|
optimize the 3-D cell culture model to measure the Cell number
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the effect of biochemical factors for glucose concentration
Time Frame: baseline, pre-intervention
|
investigate the effect of of biochemical factors to measure glucose concentration
|
baseline, pre-intervention
|
the effect of biochemical factors for glucose concentration
Time Frame: 3 month
|
investigate the effect of of biochemical factors to measure glucose concentration
|
3 month
|
the effect of biochemical factors for glucose concentration
Time Frame: 6 month
|
investigate the effect of of biochemical factors to measure glucose concentration
|
6 month
|
the effect of biochemical factors for the serum concentration of growth factors/cytokines
Time Frame: baseline, pre-intervention
|
investigate the effect of of biochemical factors to measure the serum concentration of growth factors/cytokines
|
baseline, pre-intervention
|
the effect of biochemical factors for the serum concentration of growth factors/cytokines
Time Frame: 3 month
|
investigate the effect of of biochemical factors to measure the serum concentration of growth factors/cytokines
|
3 month
|
the effect of biochemical factors for the serum concentration of growth factors/cytokines
Time Frame: 6 month
|
investigate the effect of of biochemical factors to measure the serum concentration of growth factors/cytokines
|
6 month
|
the effect of biochemical factors for the serum pH
Time Frame: 3 month
|
investigate the effect of of biochemical factors to measure the serum pH
|
3 month
|
the effect of biochemical factors for the serum pH
Time Frame: 6 month
|
investigate the effect of of biochemical factors to measure the serum pH
|
6 month
|
the effect of biochemical factors for the serum pH
Time Frame: baseline
|
investigate the effect of of biochemical factors to measure the serum pH
|
baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Hsuan-Chih Kuo, Ye,Siou-Ru
Publications and helpful links
General Publications
- Oppenheimer SB. Cellular basis of cancer metastasis: A review of fundamentals and new advances. Acta Histochem. 2006;108(5):327-34. doi: 10.1016/j.acthis.2006.03.008. Epub 2006 May 26.
- Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006 Jun;6(6):449-58. doi: 10.1038/nrc1886.
- Konstantopoulos K, Thomas SN. Cancer cells in transit: the vascular interactions of tumor cells. Annu Rev Biomed Eng. 2009;11:177-202. doi: 10.1146/annurev-bioeng-061008-124949.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202101222A3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cell Carcinoma
-
Regeneron PharmaceuticalsSanofiRecruitingBasal Cell Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States
-
Boston UniversityRecruitingSuperficial Basal Cell Carcinoma | Squamous Cell Carcinoma in SituUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage... and other conditionsCanada, United States
-
University of Kansas Medical CenterActive, not recruitingBasal Cell Carcinoma | Squamous Cell Carcinoma | Cutaneous Squamous Cell CarcinomaUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Laryngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage... and other conditionsUnited States
-
University of California, San DiegoCompletedBasal Cell Carcinoma | Squamous Cell Carcinoma in Situ
-
Emory UniversitySynta Pharmaceuticals Corp.TerminatedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage I Hypopharyngeal Squamous Cell Carcinoma | Stage I Laryngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II... and other conditionsUnited States
-
Northwestern UniversityCompletedBasal Cell Carcinoma | Squamous Cell CarcinomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Caregiver | Salivary Gland Squamous Cell Carcinoma | Malignant Head and Neck Neoplasm | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Stage... and other conditionsUnited States
Clinical Trials on CTCs isolation/purification and cell number expansion
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingGlioma | Glioblastoma | Glioma Glioblastoma MultiformeItaly
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RecruitingIntervertebral Disc Degeneration | Discogenic Pain | Discogenic DiseaseItaly
-
University Hospital, BordeauxCompletedKidney Transplant InfectionFrance
-
Al-Azhar UniversityCairo University; Ain Shams University; Wake Forest University Health Sciences; Affiliated Hospital to Academy of Military Medical SciencesUnknownFecal IncontinenceEgypt
-
University of Kansas Medical CenterIn8bio Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid LeukemiaUnited States
-
Memorial Sloan Kettering Cancer CenterTerminatedHematopoietic Stem Cell Transplant | Poor Marrow Graft FunctionUnited States
-
University of Sao PauloConselho Nacional de Desenvolvimento Científico e TecnológicoCompletedRetinal Degeneration | Primary Open-angle GlaucomaBrazil
-
Steinar AamdalTerminatedMetastatic Malignant MelanomaNorway
-
Cairo UniversityUnknownBone Resorption | Alveolar Bone Loss | Alveolar Bone Resorption | Bone Graft Failure